Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Epidemic Mitigation and Marginal Mortality Gains Using Self-Testing as a Diagnostic Intervention for Epidemic-Prone Diseases in Africa.

Diagnostics (Basel, Switzerland)·2026
Same author

The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design.

Vaccine·2026
Same author

Inclusion of young adolescents in policy development for new tuberculosis vaccines.

The Lancet. Global health·2026
Same author

Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial.

The lancet. HIV·2026
Same author

Perceived gender equitable norms and previous tuberculosis testing in Malawi: A secondary analysis of a cluster-based prevalence survey.

PLOS global public health·2026
Same author

Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa.

PLOS global public health·2026

相关实验视频

Updated: Jul 11, 2026

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

撒哈拉以南非洲的结核病:在抗逆转录病毒治疗时代的机会,挑战和变化.

Elizabeth L Corbett1, Barbara Marston, Gavin J Churchyard

  • 1London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. elc1@mweb.co.zw

Lancet (London, England)
|March 21, 2006
PubMed
概括

在非洲扩大艾滋病毒治疗提供了希望,但需要整合结核病控制. 如果不这样做,就会威胁到艾滋病毒和结核病计划.

科学领域:

  • 公共卫生 公共卫生
  • 传染性疾病 传染性疾病
  • 流行病学 流行病学

背景情况:

  • 抗逆转录病毒治疗 (ART) 计划正在非洲迅速扩大.
  • 结核病 (TB) 是非洲艾滋病毒感染者疾病和死亡的主要原因.
  • 目前的国家结核病和艾滋病控制计划对艾滋病毒诊断和结核病患者的护理的整合有限.

研究的目的:

  • 审查非洲的结核病流行病学.
  • 检查扩大艾滋病毒/艾滋病治疗的政策影响.

主要方法:

  • 关于非洲结核病流行病学的文献综述.
  • 对广泛获得抗逆转录病毒治疗的政策影响的分析.

主要成果:

  • 非洲的结核病控制策略尚未适应抗逆转录病毒疗法的可用性增加.
  • 整合的重大障碍包括药物相互作用和历史程序分离.
  • 成功整合艾滋病毒和结核病控制对于两项计划的可行性至关重要.

结论:

  • 扩大艾滋病毒治疗需要一个协调的方法来控制非洲的结核病.
  • 消除整合障碍对于防止任何计划失败至关重要.

更多相关视频

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关实验视频

Last Updated: Jul 11, 2026

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

  • 需要政策和方案的改变,以有效地管理艾滋病毒和结核病的双重负担.